Palmetto Peptides Guide to the Research Peptide AOD-9604
Research Disclaimer: AOD-9604 is sold strictly for laboratory and scientific research purposes. It is not intended for human consumption, clinical use, veterinary use, or any application outside of a controlled research setting. This content is intended for researchers, scientists, and laboratory professionals. Nothing in this guide constitutes medical advice.
Palmetto Peptides Guide to the Research Peptide AOD-9604
Last Updated: April 5, 2026 | Author: Palmetto Peptides Research Team
What Is AOD-9604? A Direct Answer for Researchers
AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal end of human growth hormone (hGH), specifically from positions 177 through 191 of the native protein. A tyrosine residue was added at the N-terminus during development, distinguishing it from the unmodified hGH fragment and giving it the designation Tyr-hGH177-191. Its CAS number is 221231-10-3, and its molecular weight is approximately 1817.12 g/mol.
The peptide was developed in the early 1990s at Monash University in Melbourne, Australia, under the direction of researchers studying which regions of the hGH molecule were responsible for metabolic signaling — specifically, fat breakdown independent of the hormone's growth-promoting effects. AOD stands for Anti-Obesity Drug, reflecting the research context in which it was originally characterized.
In preclinical studies, primarily conducted in rodent models and adipocyte (fat cell) cultures, AOD-9604 demonstrated the ability to stimulate lipolysis (the breakdown of stored fat) and inhibit lipogenesis (the conversion of non-fat nutrients into stored fat). These findings generated significant scientific interest and led to a series of clinical trials in the early 2000s.
AOD-9604 is sold strictly for scientific research purposes. It is not approved for human or veterinary use, and no information in this guide should be interpreted as a clinical recommendation or treatment protocol.
This guide compiles the most relevant publicly available research data, laboratory handling information, and quality standards to support researchers working with this compound in controlled laboratory settings.
Molecular Profile: Understanding What AOD-9604 Is at the Chemical Level
Before designing any experiment involving AOD-9604, researchers need a working understanding of its molecular identity. This section covers the essential biochemical properties.
Amino Acid Sequence
AOD-9604 consists of 16 amino acids arranged in the following sequence:
Tyr – Leu – Arg – Ile – Val – Gln – Cys – Arg – Ser – Val – Glu – Gly – Ser – Cys – Gly – Phe
In single-letter code: Y – L – R – I – V – Q – C – R – S – V – E – G – S – C – G – F
The two cysteine residues at positions 7 and 14 form an intramolecular disulfide bond — a covalent bridge that creates a small looped region within the chain. This structural feature is inherited from the native hGH molecule and contributes to the peptide's partial conformational rigidity and proteolytic resistance.
Core Molecular Parameters
| Property | Value |
|---|---|
| Molecular Formula | C₇₈H₁₂₃N₂₃O₂₃S₂ |
| Molecular Weight | ~1817.12 g/mol |
| CAS Number | 221231-10-3 |
| Amino Acid Count | 16 |
| Disulfide Bonds | 1 (Cys⁷ to Cys¹⁴) |
| Net Charge at pH 7.4 | Positive |
| Typical Solubility | Aqueous (sterile water, 0.1% acetic acid, PBS) |
| Standard Research Purity | ≥98% by HPLC |
In plain terms: Think of AOD-9604 as a precisely trimmed piece of a much larger protein. Researchers took the section of growth hormone most associated with fat metabolism, made one structural modification to improve stability, and isolated it as a standalone compound for study. The disulfide bond acts like a staple between two points in the chain, giving it a defined shape rather than a floppy linear structure.
For a detailed breakdown of the molecular structure and its research implications, see our AOD-9604 Chemical Structure and Amino Acid Sequence Analysis.
Development History: From hGH Research to Standalone Compound
Understanding how AOD-9604 came to exist helps researchers contextualize both its research applications and its limitations.
Origins at Monash University
The peptide emerged from work in the late 1980s and early 1990s focused on mapping the functional domains of human growth hormone. Scientists at Monash University, led in part by Professor Frank Ng, were investigating which specific regions of the 191-amino acid hGH molecule were responsible for different biological effects — growth promotion versus metabolic activity.
The discovery that the C-terminal region (positions 176 to 191 of the native protein) appeared to drive lipolytic activity independently of the receptor binding regions responsible for growth led to targeted synthesis of isolated fragments from this area. AOD-9604, with its N-terminal tyrosine modification, was the version ultimately advanced for further study.
Research and Development Timeline
| Period | Development Stage |
|---|---|
| Late 1980s – Early 1990s | hGH domain mapping research at Monash University |
| Mid-1990s | Synthesis and initial preclinical characterization of AOD-9604 |
| Late 1990s – Early 2000s | Rodent model studies; licensing to Metabolic Pharmaceuticals Ltd. |
| Early 2000s | Phase I and Phase IIa clinical trials in humans |
| 2004–2007 | Phase IIb trials; results published; development pathway re-evaluated |
| Post-2007 | Compound remains in active research use; not approved for any therapeutic indication |
Key takeaway for researchers: AOD-9604 has a substantial body of peer-reviewed preclinical and early clinical literature behind it. This makes it a well-characterized research compound relative to many newer synthetic peptides. However, the lack of regulatory approval for any indication means all current research use is exploratory.
For a deeper look at the synthesis methods used to produce AOD-9604 in laboratory settings, see our AOD-9604 Development History and Laboratory Synthesis Guide.
Preclinical Research Overview: What the Animal and Cell Studies Show
The bulk of published research on AOD-9604 comes from preclinical models — primarily adipocyte (fat cell) cultures and rodent studies. This section summarizes the key findings.
In Vitro: Adipocyte Studies
Laboratory studies using isolated fat cells have examined AOD-9604's effect on two key metabolic processes:
Lipolysis refers to the breakdown of stored triglycerides into free fatty acids and glycerol, which can then be used as an energy source or exported from the cell. AOD-9604 has been shown in 3T3-L1 adipocyte models (a standard differentiated fat cell line) to increase markers of lipolytic activity, including glycerol and free fatty acid release into culture media.
Lipogenesis refers to the conversion of glucose or other precursors into stored fat. In vitro data suggests that AOD-9604 may inhibit lipogenic enzyme activity under certain conditions.
The intracellular mechanism being studied involves the cAMP-PKA-HSL signaling axis. Briefly: when certain receptors on fat cells are activated, intracellular cyclic AMP (cAMP) levels rise, which activates protein kinase A (PKA), which in turn activates hormone-sensitive lipase (HSL) to begin breaking down stored fat. Research has examined whether AOD-9604 interacts with beta-adrenergic receptors along this pathway.
In plain terms: Inside fat cells, there's a biological switch that controls whether fat is stored or broken down. Some research suggests AOD-9604 may influence this switch toward breakdown, but the exact receptor pathway remains an active area of investigation.
For the full mechanistic breakdown, see our AOD-9604 In Vitro Mechanisms and Adipocyte Function Analysis.
In Vivo: Rodent Model Data
Animal studies have used several rodent model types to study AOD-9604's metabolic effects:
Diet-Induced Obesity (DIO) Models: Mice fed high-fat diets to induce obesity were administered AOD-9604 and compared to controls. Studies reported differences in body weight gain, fat mass, and adipose tissue characteristics between groups.
Beta-3 Adrenergic Receptor Knockout (β3-AR KO) Models: These genetically modified mice lack a specific receptor involved in fat metabolism. Studies using this model helped researchers examine which signaling pathways AOD-9604 depends on for its observed effects.
Genetically Obese Models (ob/ob Mice): Mice with leptin-deficiency-induced obesity were also used in early experiments.
A foundational study frequently cited in the literature is Heffernan et al. (2001), published in the Journal of Endocrinology, which examined AOD-9604 in obese rodent models and provided early data on body composition outcomes in treated versus untreated groups.
Important caveat: Data from rodent models does not directly translate to humans. Rodents and humans differ substantially in metabolic rate, adipose tissue biology, and receptor pharmacology. Researchers should not extrapolate animal findings to human outcomes.
Summary of Preclinical Research Landscape
| Model Type | Primary Variables Studied | Key Findings in Literature |
|---|---|---|
| 3T3-L1 adipocytes (in vitro) | Glycerol release, FFA output, HSL activity | Increased lipolytic markers observed |
| DIO mouse model | Body weight, fat mass, adipose morphology | Differences in fat accumulation reported |
| β3-AR KO mouse | Receptor-dependency of lipolytic effects | Partial attenuation of effects in KO animals |
| ob/ob mouse | Body composition, metabolic markers | Explored in early characterization studies |
| Phase I/IIa clinical trials | Safety, tolerability, pharmacokinetics | General safety established; efficacy endpoints mixed in Phase IIb |
For detailed study-by-study summaries, see our AOD-9604 Preclinical Animal Studies Overview and our AOD-9604 Scientific Literature Review.
AOD-9604 vs. Related Peptides: Research Context
Researchers frequently compare AOD-9604 to other peptides that appear in adjacent areas of metabolic and peptide science literature. Here is a brief orientation to avoid conflation.
AOD-9604 vs. hGH Fragment 177-191
The native hGH fragment 177-191 is the unmodified sequence from which AOD-9604 was derived. The only structural difference is the N-terminal tyrosine addition in AOD-9604. This modification affects the peptide's N-terminal chemistry, stability profile, and CAS designation, while the core lipolytic region remains intact.
AOD-9604 vs. CJC-1295
CJC-1295 is a growth hormone releasing hormone (GHRH) analog — a peptide that influences upstream signaling involved in growth hormone secretion from the pituitary. AOD-9604 is a fragment of hGH itself, acting downstream. These are entirely different compounds with different sequences, receptors, and research applications.
AOD-9604 vs. Ipamorelin
Ipamorelin is a growth hormone secretagogue — it stimulates GH release through the ghrelin receptor pathway. Again, this is upstream of where AOD-9604 operates in the growth hormone system. The two compounds are sometimes studied in combination in research settings, but they are structurally and mechanistically distinct.
AOD-9604 vs. BPC-157
BPC-157 is a pentadecapeptide (15 amino acids) derived from a gastric protein. It has been studied in wound healing, angiogenesis, and musculoskeletal tissue repair models. It shares no sequence overlap with AOD-9604 and operates through completely different pathways. The only commonality is that both are synthetic research peptides sold for laboratory use.
Comparison Summary
| Peptide | Origin | Primary Research Area | Receptor Mechanism |
|---|---|---|---|
| AOD-9604 | hGH C-terminal fragment | Lipid metabolism, lipolysis | β-adrenergic (under study) |
| hGH Fragment 177-191 | Native hGH sequence | Lipid metabolism (precursor to AOD-9604) | Similar to AOD-9604 |
| CJC-1295 | GHRH analog | GH secretion signaling | GHRH receptor |
| Ipamorelin | GH secretagogue | GH release | Ghrelin receptor (GHS-R1a) |
| BPC-157 | Gastric protein fragment | Tissue repair, angiogenesis | Multiple (VEGFR, FAK-paxillin) |
For the full comparative analysis, see our AOD-9604 vs. hGH Fragment 177-191 Research Comparison.
Laboratory Handling: Reconstitution, Storage, and Stability
Proper handling of AOD-9604 in a research environment is essential for reproducible results. This section covers the core protocols.
Reconstitution
AOD-9604 is supplied as a lyophilized (freeze-dried) powder. Before use in any assay, it must be reconstituted into solution.
Recommended solvents (in order of preference): 1. Sterile water for injection 2. 0.1–1% acetic acid in sterile water (improves initial dissolution) 3. Phosphate-buffered saline (PBS) — suitable after initial dissolution in water or acetic acid
General reconstitution steps: 1. Remove vial from cold storage and allow it to equilibrate to room temperature (approximately 15–20 minutes) before opening to avoid condensation. 2. Calculate the volume of solvent needed to achieve your target working concentration. 3. Add solvent slowly down the side of the vial — do not inject directly onto the powder. 4. Gently swirl or roll the vial. Do not vortex, which can introduce shear stress that disrupts peptide integrity. 5. Allow 5–10 minutes for complete dissolution. The solution should be clear and colorless. 6. Aliquot immediately into single-use volumes before storage.
Concentration calculation (example): If you have a 5 mg vial and want a working concentration of 1 mg/mL, add 5 mL of solvent. For a 0.5 mg/mL concentration, add 10 mL.
For step-by-step visual guidance and worked examples, see our AOD-9604 Reconstitution Protocol for Laboratory Use.
Storage and Stability
Lyophilized (powder) form:
| Condition | Duration |
|---|---|
| -20°C, sealed, dark | Up to 24 months (manufacturer-validated) |
| 4°C, sealed, dark | Short-term (weeks); not recommended for long-term |
| Room temperature | Not recommended; degradation risk increases significantly |
Reconstituted (solution) form:
| Condition | Duration |
|---|---|
| 4°C (refrigerator) | Up to 72 hours |
| -20°C (aliquoted) | Up to 4 weeks |
| -80°C (aliquoted) | Several months; preferred for long-term |
Minimize freeze-thaw cycles. Each cycle introduces the risk of peptide aggregation and loss of biological activity in assays. If you expect to use a vial over multiple experiment days, aliquot it into single-session volumes before freezing.
Signs of potential degradation: cloudiness, precipitation, color change (should remain colorless), or unusual odor. If any of these are observed, do not use the sample in quantitative assays.
For the full stability profile and degradation identification guide, see our AOD-9604 Storage and Stability Guidelines.
Research Applications: What Laboratories Use AOD-9604 For
AOD-9604 appears in the literature across several distinct research contexts. This section provides a structured orientation.
Lipolysis and Lipid Metabolism Studies
The most established application of AOD-9604 in research is as a tool compound for studying lipid mobilization in fat cell models. It is used to probe signaling cascades involved in triglyceride breakdown, particularly the cAMP-PKA-HSL axis in differentiated adipocyte cultures.
Structure-Activity Relationship (SAR) Research
Because AOD-9604 is derived from a well-characterized parent protein (hGH) and differs from the native fragment by a single modification, it serves as a useful reference point in SAR studies comparing peptide modifications to biological activity. Researchers designing novel fragments of hGH often include AOD-9604 as a benchmark compound.
Receptor Binding Studies
The exact receptor target of AOD-9604 remains an active area of investigation. It does not appear to bind the GH receptor (GHR) in the same manner as full-length hGH, which is one reason it lacks hGH's growth-promoting effects in preclinical models. Radioligand binding assays and competitive displacement studies have been used to probe its receptor interactions.
Metabolic Obesity Model Research
In animal model contexts, AOD-9604 has been used to investigate diet-induced obesity, adipose tissue remodeling, and the relationship between GH-related signaling and metabolic outcomes. It serves as a pharmacological tool rather than a therapeutic agent in these settings.
Reference Compound Applications
Given its well-documented preclinical profile and clinical trial history, AOD-9604 is sometimes used as a reference compound in research programs evaluating novel peptide fragments in the same structural family.
For a detailed breakdown of assay compatibility and application-specific protocols, see our AOD-9604 Laboratory Applications and Metabolic Pathway Research Guide.
Quality Standards: What Research-Grade AOD-9604 Should Look Like
Not all peptide suppliers produce material of equivalent quality. For researchers making purchasing decisions, this section outlines the minimum documentation and purity standards that a credible supplier should provide.
Purity
Research-grade AOD-9604 should meet a minimum HPLC purity of 98% or greater. This is the standard threshold at which most academic and pharmaceutical research laboratories work. Material below 95% introduces enough impurity risk that quantitative assay results become unreliable — you cannot be certain whether you are measuring an effect from AOD-9604 itself or from a co-eluting impurity.
How purity is calculated:
HPLC purity is expressed as the percentage of the target peak area relative to total peak area in the chromatogram:
Purity (%) = (Target Peak Area ÷ Total Peak Area) × 100
A credible COA will include the actual chromatogram or at minimum the retention time and the calculated purity value.
Certificate of Analysis (COA) Requirements
| COA Element | Minimum Standard | Better Standard |
|---|---|---|
| HPLC purity value | ≥98% stated | Chromatogram image included |
| Mass spectrometry | Molecular weight confirmation | Full MS/MS data |
| Net peptide content | Stated (not just gross weight) | Calculated with moisture and acetate corrections |
| Moisture content | Stated | Karl Fischer method specified |
| Batch number | Present | Traceable to production date |
| Testing laboratory | Named | Independent third-party, ISO/IEC 17025 accredited |
| Sterility/endotoxin | Not always required | Included for injectable-grade research use |
Red Flags in Supplier Documentation
- Purity stated without an associated method (HPLC, not just "tested")
- No mass spectrometry data
- "In-house" testing only with no third-party verification
- Generic COA not tied to a specific batch number
- No net peptide content disclosure (gross weight and net peptide content are not the same)
- Reluctance to share documentation on request
Palmetto Peptides provides batch-specific COA documentation for all AOD-9604 orders, including HPLC chromatogram data and independent third-party mass spectrometry confirmation.
For the complete supplier evaluation framework, see our AOD-9604 Supplier Evaluation and Quality Testing Guide and our AOD-9604 Purity Standards, Quality Testing, and COA Guide.
Combination Research: AOD-9604 Alongside Other Compounds
Some researchers study AOD-9604 alongside other peptides or research compounds in multi-arm experimental designs. A few considerations apply.
Buffer compatibility: AOD-9604 is stable in PBS and Tris-HCl buffers commonly used in laboratory settings. Researchers should verify compatibility with any co-administered compound before combining in solution — some peptides may interact at the solvent interface or affect each other's solubility.
Disulfide exchange risk: AOD-9604 contains an intramolecular disulfide bond (Cys⁷ to Cys¹⁴). When combined in solution with other cysteine-containing peptides under oxidizing conditions, there is a theoretical risk of intermolecular disulfide exchange. This can be mitigated by working under reducing conditions or preparing combination solutions fresh immediately before use.
Experimental design considerations: Multi-compound studies require appropriate control arms. A minimum five-group design is typically used: vehicle only, compound A alone, compound B alone, the combination, and a positive control if available. This structure allows researchers to isolate individual versus combined effects.
For commonly researched combination protocols and buffer compatibility data, see our AOD-9604 Interactions and Combination Considerations for Laboratory Research.
Sourcing AOD-9604 for Research
Researchers sourcing AOD-9604 should prioritize documentation quality and supplier transparency over price alone. The reproducibility of your research depends directly on the consistency and purity of the compound you use.
What to Look for in a Research Peptide Supplier
- Batch-specific COA available before or at time of purchase
- Independent third-party HPLC and mass spectrometry testing
- Net peptide content disclosed
- Clear research-use-only terms of sale
- Responsive to technical questions from research staff
Palmetto Peptides AOD-9604
Palmetto Peptides offers AOD-9604 for research purposes with full COA transparency. Every batch is tested by an independent third-party laboratory for HPLC purity and molecular weight confirmation via mass spectrometry. We supply exclusively to researchers for scientific use.
Related Research Peptides Available from Palmetto Peptides
Researchers working with AOD-9604 may also be investigating other peptides relevant to metabolic, tissue repair, or growth hormone pathway research:
- BPC-157 — pentadecapeptide studied in tissue repair and angiogenesis models
- TB-500 — thymosin beta-4 fragment studied in actin regulation and wound healing research
- CJC-1295 — GHRH analog studied in growth hormone secretion models
- Ipamorelin — GH secretagogue studied in GH release and metabolic research
- IGF-1 LR3 — long-acting IGF-1 variant studied in anabolic and growth signaling models
- GHK-Cu — copper tripeptide studied in wound healing, skin biology, and gene expression research
AOD-9604 Research Summary
What it is: A 16-amino acid synthetic peptide fragment derived from hGH residues 177-191, with a tyrosine N-terminal addition. CAS 221231-10-3. MW ~1817.12 g/mol.
Where it came from: Developed at Monash University in the 1990s; advanced through Phase IIb clinical trials by Metabolic Pharmaceuticals Ltd. in the early 2000s. Not approved for any therapeutic use.
What the research shows: Preclinical data in rodent models and adipocyte cultures suggests lipolytic activity and lipogenesis inhibition. Clinical trial results were mixed on efficacy endpoints. All data is from controlled research settings.
What researchers use it for: Lipid metabolism studies, SAR comparisons, receptor binding assays, obesity model research, and as a reference compound in fragment-based hGH research.
How to handle it: Lyophilized powder stored at -20°C. Reconstitute in sterile water or dilute acetic acid. Aliquot before storage. Avoid freeze-thaw cycling. Minimum 98% HPLC purity for reliable research use.
How to evaluate it: Require a batch-specific COA with HPLC chromatogram, MS confirmation, net peptide content, and independent third-party testing.
Frequently Asked Questions About AOD-9604
What is AOD-9604? AOD-9604 is a synthetic 16-amino acid peptide fragment derived from the C-terminal region of human growth hormone (hGH), spanning positions 177 through 191 with a tyrosine residue added at the N-terminus. It was developed at Monash University in Australia and has been studied preclinically for its lipolytic properties in adipocyte cell models and rodent obesity studies. It is sold exclusively for scientific research purposes.
How does AOD-9604 differ from the native hGH fragment 177-191? AOD-9604 differs from the native hGH fragment 177-191 primarily by the addition of a tyrosine residue at the N-terminus. This modification was introduced to improve stability and gives the peptide its distinct CAS number. The modification does not appear to substantially alter the core lipolytic signaling behavior observed in preclinical research, but it does affect the peptide's biochemical and pharmacokinetic profile.
What does the preclinical research on AOD-9604 show? Preclinical research in rodent models has shown that AOD-9604 can stimulate lipolysis and inhibit lipogenesis in adipose tissue. Studies using diet-induced obese mice and beta-3 adrenergic receptor knockout models demonstrated differences in body composition metrics between treated and control animals. These findings are from animal models and do not establish efficacy or safety in humans.
What purity standard should research-grade AOD-9604 meet? Research-grade AOD-9604 should meet a minimum HPLC purity of 98% or higher. The certificate of analysis should include HPLC chromatogram data, mass spectrometry confirmation of molecular weight, net peptide content, moisture content, and sterility testing if applicable.
How should AOD-9604 be stored in a laboratory setting? Lyophilized AOD-9604 powder should be stored at -20°C for long-term stability, protected from light and moisture. Once reconstituted, aliquot into single-use volumes, store at 4°C for up to 72 hours, and at -80°C for longer-term storage. Minimize freeze-thaw cycles.
What solvents are used to reconstitute AOD-9604? AOD-9604 is typically reconstituted using sterile water or 0.1–1% acetic acid in water. PBS is suitable after initial dissolution. Organic solvents like DMSO are generally not required.
Is AOD-9604 the same as CJC-1295 or BPC-157? No. These are distinct compounds with different sequences, mechanisms, and research profiles. AOD-9604 is an hGH fragment studied for lipolytic activity. CJC-1295 is a GHRH analog. BPC-157 is derived from a gastric protein and studied in tissue repair models.
Where can researchers source AOD-9604 for laboratory use? Researchers should source AOD-9604 from suppliers who provide batch-specific certificates of analysis, independent third-party HPLC and mass spectrometry testing, and research-use-only documentation. Palmetto Peptides offers AOD-9604 for research purposes with full COA transparency and third-party purity verification.
Peer-Reviewed Citations
Heffernan, M., Thorburn, A.W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M.J., & Ng, F.M. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 177–191. Journal of Endocrinology, 170(2), 383–395. https://doi.org/10.1677/joe.0.1700383
Ng, F.M., Sun, J., Sharma, L., Libinaka, R., Jiang, W.J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278. https://doi.org/10.1159/000023567
Stier, H., Vos, E., & Kenley, D. (2013). Safety and tolerability of the growth hormone fragment AOD9604 in healthy adults. Clinical Obesity, 3(1-2), 6–12. https://doi.org/10.1111/cob.12010
Siu, A.H., Tsui, S., & Ng, F.M. (1998). Identification of the lipolytic domain of the human growth hormone molecule. International Journal of Obesity, 22(3), 181–188. https://doi.org/10.1038/sj.ijo.0800569
Research Use Only Disclaimer: AOD-9604 is intended solely for use in controlled laboratory and scientific research settings by qualified professionals. It has not been approved by the FDA or any regulatory authority for human or veterinary use, and it is not intended to diagnose, treat, cure, or prevent any disease or condition. All research involving this compound should be conducted in accordance with applicable laws, institutional review board (IRB) protocols, and safety guidelines. Palmetto Peptides makes no claims regarding the safety or efficacy of this compound in humans or animals.
Author: Palmetto Peptides Research Team Last Updated: April 5, 2026
Explore the full AOD-9604 research cluster: - AOD-9604 Chemical Structure and Amino Acid Sequence Analysis - AOD-9604 Development History and Laboratory Synthesis - AOD-9604 Preclinical Animal Studies Overview - AOD-9604 vs. hGH Fragment 177-191 Research Comparison - AOD-9604 In Vitro Mechanisms and Adipocyte Function - AOD-9604 Purity Standards and COA Guide - AOD-9604 Reconstitution Protocol for Laboratories - AOD-9604 Storage and Stability Guidelines - AOD-9604 Laboratory Applications and Metabolic Pathway Research - AOD-9604 Supplier Evaluation Guide - AOD-9604 Advanced Synthesis Techniques - AOD-9604 Interactions and Combination Considerations - AOD-9604 Scientific Literature Review